X0306 4 2018-01-25 0 0001566044 Menlo Therapeutics, Inc. MNLO 0001618789 Vivo Capital VIII, LLC 505 HAMILTON AVE, SUITE 207 PALO ALTO CA 0 0 1 0 0001628048 Vivo Capital Surplus Fund VIII, L.P. C/O VIVO CAPITAL VIII, LLC 505 HAMILTON AVE, SUITE 207 PALO ALTO CA 0 0 1 0 0001618788 Vivo Capital Fund VIII, L.P. 505 HAMILTON AVE, SUITE 207 PALO ALTO CA 0 0 1 0 Common Stock 2018-01-25 4 P 0 258432 17.00 A 258432 I By Vivo Capital Fund VIII, L.P. Common Stock 2018-01-25 4 P 0 35686 17.00 A 35686 I By Vivo Capital Surplus Fund III, L.P. Common Stock 2018-01-29 4 C 0 2348550 A 2606982 I By Vivo Capital Fund VIII, L.P. Common Stock 2018-01-29 4 C 0 324306 A 359992 I By Vivo Capital Surplus Fund III, L.P. Common Stock 2018-01-29 4 C 0 917559 A 3524541 I By Vivo Capital Fund VIII, L.P. Common Stock 2018-01-29 4 C 0 126703 A 486695 I By Vivo Capital Surplus Fund III, L.P. Series B Preferred Stock 2018-01-29 4 C 0 6335215 0.00 D Common Stock 2348550 0 I By Vivo Capital Fund VIII, L.P. Series B Preferred Stock 2018-01-29 4 C 0 874817 0.00 D Common Stock 324306 0 I By Vivo Capital Surplus Fund III, L.P. Series C Preferred Stock 2018-01-29 4 C 0 2475118 0.00 D Common Stock 917559 0 I By Vivo Capital Fund VIII, L.P. Series C Preferred Stock 2018-01-29 4 C 0 341784 0.00 D Common Stock 126703 0 I By Vivo Capital Surplus Fund III, L.P. Vivo Capital VIII, LLC ("Vivo LLC") is the general partner of each of Vivo Capital Fund VIII, L.P. ("VCF") and Vivo Capital Surplus Fund VIII, L.P. ("VCSF"), the record holder of the securities, and disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Albert Cha, a director of the issuer, Frank Kung, Edgar Engleman, Chen Yu and Shan Fu are managing members of Vivo LLC and may be deemed to share voting and dispositive power over the securities held by VCF and VCSF. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock. /s/ Albert Cha as a managing member of Vivo Capital VIII, LLC 2018-01-29 /s/ Albert Cha as a managing member of Vivo Capital VIII, LLC, the general partner of Vivo Capital Surplus Fund VIII, L.P. 2018-01-29 /s/ Albert Cha as a managing member of Vivo Capital VIII, LLC, the general partner of Vivo Capital Fund VIII, L.P. 2018-01-29